Linalool-13C3

CAT: 0804-HY-N0368S1Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-N0368S1Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Linalool-13C3 is 13C labeled Linalool (HY-N0368) . Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities[1][2][3][4][5].
UNSPSC
12352211
Target
Apoptosis; Bacterial; Endogenous Metabolite; iGluR; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/linalool-13c3.html
Solubility
10 mM in DMSO
Smiles
C=CC(O)(C)CC/C=[13C]([13CH3])/[13CH3]
Molecular Formula
C7 13C3H18O
Molecular Weight
157.23
References & Citations
[1]Oner Z1, et al. The protective and therapeutic effects of linalool against doxorubicin-induced cardiotoxicity in Wistar albino rats. Hum Exp Toxicol. 2019 Apr 12:960327119842634.|[2]Jana S, et al. Antitumorigenic potential of linalool is accompanied by modulation of oxidative stress: an in vivo study in sarcoma-180 solid tumor model. Nutr Cancer. 2014;66 (5) :835-48. |[3]Jun HJ, et al. Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55 (6) :1098-110.|[4]Rodenak-Kladniew B, et al. Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells. Heliyon. 2020 Dec 15;6 (12) :e05639. |[5]An Q, et al. Recent updates on bioactive properties of linalool. Food Funct. 2021 Nov 1;12 (21) :10370-10389. |[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-N0368S2Linalool-d6
HY-116195-01L-Linalool
HY-N0368SLinalool-d3
HY-N0368R-01Linalool (Standard)
HY-W412861-01(S) -Linalool
HY-152052S-01Linalool-d5
HY-N9502-01Linalool oxide
HY-116195R-01L-Linalool (Standard)
HY-W588273-01Trans-Linalool oxide
HY-W588272Cis-Linalool oxide

Alternative Products

CatalogName
281324-01Linalool
sc-250249(-) -Linalool
sc-506060(−) -Linalool

Popular Products